Peptides and Injury Recovery: What the Evidence Actually Shows

Several clients have approached us recently asking about peptides like BPC-157 and TB-500, usually after seeing them online as a way to heal faster from injuries like tendon tears, ligament damage, or an ACL reconstruction. Almost as often, the question is slightly different: whether peptides like CJC-1295, ipamorelin, or MK-677 are worth trying to build muscle, improve performance, or just feel and function better overall. Because these questions keep coming up together, we reviewed the research on all three claims properly, rather than relying on marketing.

What are these peptides, and what are they claiming?

To make sense of any of the claims, it helps to start with what a peptide actually is in the body, because none of this is as exotic as the marketing makes it out to be.

Amino acids are the basic building blocks the body uses to make proteins. There are 20 of them, and while we can make some ourselves, the rest, known as the "essential" amino acids, have to come from food, mainly protein sources like meat, eggs, dairy, legumes, and grains. Digestion breaks that dietary protein down, using stomach acid and a set of digestive enzymes, into individual amino acids and very small fragments, which the body then absorbs and uses to rebuild whatever it needs next: new muscle tissue, enzymes, hormones, immune cells, and so on.

A peptide is simply a short chain of amino acids linked together, usually between two and fifty. A protein is really just a longer version of the same basic thing. The body constantly builds and uses its own peptides for essential jobs. Insulin and glucagon, which manage blood sugar, are peptides. Growth hormone is a peptide. Many of the signalling molecules the immune system uses to coordinate a response are peptides. Even the collagen that makes up tendons, ligaments, and skin is built from chains of amino acids. None of that is unusual on its own; it's how the body runs day to day.

What's sold online as BPC-157, TB-500, CJC-1295, and similar names are synthetic, lab-made peptides designed to mimic or nudge one of these existing signalling pathways, usually ones involved in tissue repair, inflammation, or hormone release. They tend to fall into a few groups. Injury-recovery peptides like BPC-157 and TB-500 (thymosin beta-4) are promoted for tendon, ligament, and tissue repair. Growth-hormone-related peptides like CJC-1295, ipamorelin, and MK-677 are promoted for building muscle, improving body composition, and boosting athletic performance. And there's a broader category, including things like GHK-Cu, promoted more generally for anti-ageing, energy, sleep, immune function, and overall wellness. Most are sold online as injectable "research chemicals," often alongside confident before-and-after style claims.

What actually happens when you inject one

This part doesn't get explained very often, and it matters for understanding both the claims and the evidence behind them.

Peptides, as a class of molecules, are destroyed almost immediately if swallowed, generally with an oral bioavailability of less than one to two per cent. Stomach acid and digestive enzymes exist specifically to break protein and peptide chains apart into individual amino acids, which is exactly what they do to most peptide products before they can reach the bloodstream intact. That's the practical reason these products are sold as injectables rather than tablets: injecting one under the skin, into muscle, or into a joint bypasses digestion entirely and gets it into the bloodstream, or the local tissue, still in one piece.

Once it's in the body, though, nothing particularly protective or dramatic happens. The same enzymes that break down protein during digestion (called proteases, or peptidases) also circulate in the blood and tissues, and they start breaking an injected peptide apart the moment it arrives. The kidneys also filter small molecules like peptides out of the blood fairly efficiently. This is why most peptides have a very short half-life, often just minutes: BPC-157, for example, has a plasma half-life of under 30 minutes, something we'll come back to below. Whatever biological effect a peptide is going to have has to happen inside that short window, by finding and binding to a specific receptor on a cell and triggering a response, before the body clears it out. (MK-677, covered further down, is a bit different, since it's a small molecule rather than a classic peptide, which is why it can be taken as a tablet and still survive long enough to work.)

Eventually, whether the peptide finds its target receptor or not, it gets broken down into the same plain amino acids that come from digesting an ordinary meal, and those amino acids rejoin the body's normal pool, ready to be used for whatever it needs next. At that basic chemical level, an injected "healing peptide" and a glass of milk contribute the same raw materials. The entire therapeutic claim rests on what happens in that brief window before breakdown, which is exactly why the quality of the human evidence matters so much, and why a peptide showing promise in a laboratory doesn't automatically mean it does something useful, or safe, once it's actually injected into a person.

Peptides for injury recovery: what the research shows

This is where there's now a decent amount of 2026 research to look at, and it's worth going through specifically rather than just saying "the evidence is weak."

The most useful starting point is a 2026 scoping review published in the American Journal of Sports Medicine by a team from UCLA's orthopaedic surgery department. They set out to summarise the existing peer-reviewed data on six of these peptides (BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu) for musculoskeletal recovery. Across everything they found, 67% of the published research used preclinical animal models, mostly rats, each showing some promising but variable effect on tendon, muscle, bone, or ligament healing in those animals. Human research was limited to a handful of studies, most without robust controls, and the findings were described as showing "modest improvements at best" for things like bone health and degenerative knee pain. The authors' own conclusion was direct: these peptide supplements "should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care."

BPC-157 specifically has its own dedicated systematic review, published this year in a major orthopaedic sports medicine journal. The authors screened 544 articles and narrowed them to 36 studies that met their criteria; of those, 35 were preclinical, and only 1 was human. That single human study looked at 12 people with chronic knee pain who received an intra-articular injection, and 7 reported less pain for more than six months. That's a meaningful result for those individuals, but it's a small, uncontrolled case series measuring pain, not a trial measuring whether any tissue actually healed differently. A separate 2026 pharmaceutical review looking specifically at BPC-157's development as a drug found that, across every published pilot study to date, fewer than 30 human subjects in total have ever been studied, and that its short half-life, the under-30-minute clearance time mentioned above, still isn't properly matched up with how long its effects are claimed to last.

We also specifically looked for any study, animal or human, that has tested these peptides in an ACL tear or reconstruction, and couldn't find one. For context, even the biological treatments that are used clinically around ACL surgery, like platelet-rich plasma injections, still have what researchers describe as limited or equivocal evidence after years of proper trials. That's a useful yardstick: if treatments given by a doctor, with standardised preparation and real oversight, are still debated, a self-injected product with no completed human trials in this area is a long way further back.

Peptides for building muscle and improving performance

This is a slightly different question, and the research here is more developed in one specific case, which makes it a genuinely useful example.

A structured review published this year in JBJS Reviews, from the Steadman Philippon Research Institute (a well-known sports medicine research group), grouped the main performance- and recovery-related peptides into functional classes and looked at the human evidence for each. They concluded that growth-hormone axis secretagogues, including CJC-1295, ipamorelin, and tesamorelin, "remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions." Of everything they reviewed, the only class with genuinely reproducible randomised human evidence was GLP-1 receptor agonists (the semaglutide-type medications), and even there, the benefit was weight-loss driven, not a direct effect on muscle or tissue.

The most informative single piece of evidence on this topic is actually a well-designed, two-year, placebo-controlled clinical trial of MK-677 (an oral growth-hormone secretagogue, chemically different to an injectable but working on a similar pathway), published in the Annals of Internal Medicine. It's worth describing properly because it shows both sides of the picture. In 65 healthy older adults, MK-677 significantly increased fat-free mass compared to placebo over a year (a gain of about 1.1kg versus a loss of about 0.5kg in the placebo group), and it raised growth hormone and IGF-1 levels back into a youthful range. That sounds like a clear win. But the same trial found that this increase in fat-free mass did not translate into any measurable improvement in strength or physical function, and it came with a cost: fasting blood glucose rose, insulin sensitivity dropped, cortisol increased, and the most common side effects were increased appetite, fluid retention, and joint pain. In other words, more lean tissue showed up on the scans, but it didn't make anyone measurably stronger, and it nudged several metabolic markers in the wrong direction.

A separate 2026 critical review of peptide use in recreational and competitive sport reached a similarly cautious conclusion, noting that most of the studies these claims are based on used standard therapeutic doses under medical supervision, not the higher, stacked, self-administered doses typical in gyms and online communities, and that the research gap on what those higher doses actually do to the body is substantial. The review also pointed out that these peptides sit on antidoping prohibited lists, which matters for anyone training or competing under drug-testing rules.

What about general health, anti-ageing and wellness claims?

Beyond injury and muscle, peptides are also being promoted more broadly for things like energy, sleep, cognitive function, immune support, and general anti-ageing. This is probably the softest end of the claims, and it's where doctors writing on the topic this year have been most consistent in their caution.

A Harvard Health review published this year summarised it plainly: most of the evidence behind these broader wellness claims comes from test-tube and animal studies, with human trials largely absent, making it impossible to draw definitive conclusions at this point. A physician quoted in the same piece put it directly: those health claims "have not been vetted by any expert group." Reported side effects across the wellness-peptide category include nausea, gastrointestinal upset, headaches, and injection-site irritation, along with a real risk of contamination in products made and shipped without proper oversight. A separate doctor-focused piece on the same trend made a similar point about newer peptides specifically: most of what exists is still animal data, and even the handful of human studies behind recovery-focused peptides involve very small numbers of people, so there's "nothing substantial to show these results would translate to humans."

There are some exceptions worth being fair about. Topical, cosmetic-grade copper peptides like GHK-Cu have a longer, more established research history in skin and wound healing specifically, which is a genuinely different evidence picture than injecting the same peptide for broader "anti-ageing" or systemic health claims. That distinction, between a well-studied topical use and a loosely related injectable claim, is a good example of why it's worth looking at what's actually been studied rather than assuming a peptide's evidence transfers across every use it's marketed for.

Where this leaves exercise-based rehab, training, and general health

Across this research, the same pattern keeps showing up. A consistent gap exists between how confidently these peptides are marketed across recovery, muscle building, and general wellness, and how thin the human evidence is behind each specific claim. Even in the one case with a genuinely well-designed human trial, the headline result (more lean mass) didn't hold up once researchers checked whether it actually made anyone stronger.

What we can say with far more confidence is that the fundamentals haven't changed. For recovery from an injury like an ACL tear, progressive, well-structured loading, criteria-based strength and movement testing, and a gradual build back towards sport or activity remain the best-supported way to recover function over time. For building real, functional muscle, progressive resistance training with adequate protein and recovery remains the best-studied and most reliable approach. And for general health, the strongest evidence still points to the least exciting things: consistent movement, sleep, and long-term strength maintenance. None of that is as exciting as a quick-fix injection, but it's what the current evidence actually supports.

If you're recovering from an injury, want to build strength and muscle properly, or want a program built on what has evidence behind it, our Accredited Exercise Physiologists would be glad to help. We see clients across Thornleigh, Collaroy and Frenchs Forest, with funding options including Medicare Chronic Disease Management plans, DVA, NDIS, Workers Compensation and private appointments. Get in touch to find a time that works for you.